{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '137', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', \"causality attribution may be assigned to a single agent if in the investigator's opinion,\", 'there is sufficient data to support full attribution of the AE to the single agent.', 'Follow-up of AE and SAE', 'The investigator is obligated to perform or arrange for the conduct of supplemental', 'measurements and/or evaluations as medically indicated or as requested by Sponsor to', 'elucidate the nature and/or causality of the AE or SAE as fully as possible. This may', 'include additional laboratory tests or investigations, histopathological examinations, or', 'consultation with other health care professionals.', 'New or updated information will be recorded in the CRF.', 'The investigator will submit any updated SAE data to the Sponsor within 24 hours of', 'receipt of the information.', '10.3.5', 'Reporting of AEs, SAEs, and Other Reportable Safety Events to the Sponsor', 'AE, SAE, and other reportable safety event reporting to Sponsor via electronic data', 'collection tool', 'The primary mechanism for reporting to the Sponsor will be the electronic data collection', '(EDC) tool.', 'Electronic reporting procedures can be found in the EDC data entry guidelines (or', 'equivalent).', 'If the electronic system is unavailable for more than 24 hours, then the site will use', 'the paper AE Reporting form.', 'Reference Section 8.4.1 for reporting time requirements.', 'The site will enter the SAE data into the electronic system as soon as it becomes', 'available.', 'After the study is completed at a given site, the EDC tool will be taken off-line to prevent', 'the entry of new data or changes to existing data.', 'If a site receives a report of a new SAE from a study participant or receives updated data', 'on a previously reported SAE after the EDC tool has been taken off-line, then the site can', 'report this information on a paper SAE form or by telephone (see next section).', 'Contacts for SAE reporting can be found in the Investigator Study File Binder (or', 'equivalent).', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '138', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'SAE reporting to the Sponsor via paper CRF', 'If the EDC tool is not operational, facsimile transmission or secure e-mail of the SAE', 'paper CRF is the preferred method to transmit this information to the Sponsor.', 'In rare circumstances and in the absence of facsimile equipment, notification by', 'telephone is acceptable with a copy of the SAE data collection tool sent by overnight', 'mail or courier service.', 'Initial notification via telephone does not replace the need for the investigator to', 'complete and sign the SAE CRF pages within the designated reporting time frames.', 'Contacts and instructions for SAE reporting and paper reporting procedures can be found', 'in the Investigator Study File Binder (or equivalent).', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '139', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '10.4', 'Appendix 4: Device Events, Adverse Device Events, and Medical Device', 'Incidents: Definitions, Collection, and Documentation', 'This section is not applicable.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}